Additionally, a DNA methylation–based classification and TERT promoter mutation status analysis are among the most promising advances with the potential to further refine the prognostic evaluation of meningiomas [5, 15] but currently do not provide a target for treatment. The gene discussed is TERT; the disease is meningioma.